Jack Liang is the Founding Partner of Pacific 8 Ventures, a venture capital firm he co-established in 2014 with Chris. See sector focus and contact routes.
Jack Liang is the Founding Partner of Pacific 8 Ventures, a venture capital firm he co-established in 2014 with Chris Shu and Ser-Chen Fu, MD, after holding director roles at PerkinElmer and CambridgeSoft and consulting at IDBS. He invests primarily at the seed stage in early-stage companies operating at the nexus of disruptive technology platforms and biology or medicine, with a global approach that emphasizes the U.S. market and the Greater China region. The firm’s historical average check size is approximately $12.7 million, and Pacific 8 often acts as the first institutional investor in these ventures. Notable portfolio companies include Mammoth Biosciences, which pioneers CRISPR-based diagnostics; BillionToOne, a leader in prenatal testing; Fauna Bio, which leverages mammalian genetic data for therapeutics; and Dorian Therapeutics, focused on anti-aging technologies. Liang’s distinctive point of view centers on backing ventures that apply advanced technologies to solve complex challenges in therapeutics, diagnostics, and health services. While he has not published public writing cited in available sources, his professional profile highlights a focus on
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in New York.
Investors like Jack Liang · Full investor directory · Investor access · Company funding database